

FOI REF: 25/311

16<sup>th</sup> May 2025

Tel: 0300 131 4500  
Website: [www.esht.nhs.uk](http://www.esht.nhs.uk)

## FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

- 1) Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.

179.

- 2) Of the multiple myeloma patients treated over the past 6 months, how many were treated with the following:

•	Any other systemic anti-cancer therapy	6
•	Belantamab Mafodotin [Blenrep]	0
•	Belantamab Mafodotin [Blenrep] with bortezomib and dexamethasone	0
•	Belantamab Mafodotin [Blenrep] with pomalidomide and Dexamethasone	0
•	Bortezomib [Velcade] monotherapy or with dexamethasone	1
•	Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd)	0
•	Bortezomib, thalidomide and dexamethasone [VTD]	4
•	Carfilzomib [Kyprolis] and dexamethasone	0
•	Carfilzomib [Kyprolis], Lenalidomide [Revlimid] and dexamethasone	0
•	Daratamumab [Darzalex] with Lenalidomide [Revlimid] and dexamethasone	23
•	Daratumumab [Darzalex] monotherapy	7

Cont.../

•	<b>Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd)</b>	<b>20</b>
•	<b>Daratumumab [Darzalex], Bortezomib Velcade], thalidomide and dexamethasone (known as Dara-VTd)</b>	<b>0</b>
•	<b>Elranatamab</b>	<b>9</b>
•	<b>Idecabtagene vicleucel [Abecma]</b>	<b>0</b>
•	<b>Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd)</b>	<b>8</b>
•	<b>Ixazomib [Ninlaro], Lenalidomide [Revlimid] and dexamethasone (known as IRd)</b>	<b>12</b>
•	<b>Lenalidomide [Revlimid] and dexamethasone</b>	<b>60</b>
•	<b>Lenalidomide [Revlimid] monotherapy</b>	<b>7</b>
•	<b>Panobinostat in combination with Bortezomib and Dezamethasone</b>	<b>1</b>
•	<b>Pomalidomide [Imnovid] and dexamethasone</b>	<b>3</b>
•	<b>Selinexor and dexamethasone</b>	<b>1</b>
•	<b>Selinexor, Bortexomiv [Velcade] and dexamethasone</b>	<b>6</b>
•	<b>Talquetamab</b>	<b>0</b>
•	<b>Teclistamab [Tecvayli]</b>	<b>0</b>

If I can be of any further assistance, please do not hesitate to contact me.

Should you be dissatisfied with the Trust's response to your request, you have the right to request an internal review. Please write to the Freedom of Information Department ([esh-tr.foi@nhs.net](mailto:esh-tr.foi@nhs.net)), quoting the above reference, within 40 working days. The Trust is not obliged to accept an internal review after this date.

Should you still be dissatisfied with your FOI request, you have the right of complaint to the Information Commissioner at the following address:

The Information Commissioner's Office  
Wycliffe House  
Water Lane  
Wilmslow  
Cheshire SK9 5AF

Telephone: 0303 123 1113

Yours sincerely

Freedom of Information Department  
[esh-tr.foi@nhs.net](mailto:esh-tr.foi@nhs.net)